#Canada #financial results #revenue growth #Laval #Bausch Health

Bausch Health Companies Inc. Reports Strong Q1 2026 Results

On April 29, 2026, Bausch Health Companies Inc. announced its financial results for the first quarter of 2026, showcasing a noteworthy growth trajectory amid challenging circumstances. The company's consolidated revenues for the quarter reached $2.52 billion, marking a 12% increase year-over-year on a reported basis. Also notable was the 7% growth in organic revenues after adjusting for acquisitions, foreign exchange fluctuations, and divestitures.

Despite this growth in revenue, Bausch Health faced substantial challenges, including a GAAP net loss attributable to Bausch Health of $1.423 billion, which equates to a loss of $3.82 per share. This drastic figure was significantly influenced by a goodwill impairment charge of $1.426 billion linked to the company’s Salix segment, primarily affecting its RED-C program. This impairment charge overshadowed the otherwise positive earnings report, highlighting the volatile nature of the pharmaceutical industry.

Revenue Breakdown by Segment

In more detail, the financial performance was diverse across various segments. The Bausch Health segment (excluding Bausch + Lomb) reported revenues of $1.28 billion, up 14% year-over-year. The standout performer was the Salix segment, which generated $639 million, reflecting an impressive 18% increase primarily driven by robust sales of Xifaxan®. Meanwhile, the Solta Medical segment exhibited a remarkable growth of 51% year-over-year, climbing to $171 million thanks to the acquisition of Shibo’s full-service aesthetics business.

Conversely, the Diversified segment saw a decline of 10%, dropping to $185 million, indicating challenges in certain categories compared to the previous year. The Bausch + Lomb segment also performed well, achieving revenues of $1.24 billion, a rise of 9% over the previous year.

Adjusted Earnings and Future Outlook

In contrast to the challenging GAAP figures, Bausch Health's adjusted earnings per diluted share (non-GAAP) stood at $0.78, an increase of 32% compared to $0.59 from the same period last year. The consolidated adjusted EBITDA attributable to Bausch Health was reported at $837 million, reflecting a 27% growth year-over-year. This adjusted figure illustrates the company’s operational resilience amid its reported losses.

CEO Thomas J. Appio emphasized the company's strategic execution and disciplined approach as the driving forces behind these positive results, reaffirming the company's outlook for the full year 2026. Bausch Health continues to prioritize investments in its product pipeline, which includes advancements in larsucosterol geared towards treating alcohol-associated hepatitis. The company's commitment to pursuing strategic business development opportunities aligns with a broader goal to enhance shareholder value.

Concluding Remarks

Despite the major challenges reflected in the net loss due to significant one-time charges, Bausch Health demonstrated promising revenue growth and operational scalability in its diverse market segments. As the company navigates these complexities, its strategy to solidify its financial position and expand its product offerings remains focused on delivering long-term value to stakeholders. For stakeholders in health care and investment sectors, this report serves as an insight into Bausch Health's current standing and future direction, reflecting both the resilience and volatility of the pharmaceutical industry.